Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.
Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, Beckham SW, Hammond P, Margolis D, Murray M. Kerrigan D, et al. Among authors: margolis d. AIDS Behav. 2018 Nov;22(11):3540-3549. doi: 10.1007/s10461-017-2017-x. AIDS Behav. 2018. PMID: 29290075 Free PMC article.
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, Swindells S, Bredeek UF, García Del Toro M, Garcia Gasalla M, Rubio García R, Antela A, Hudson K, Griffith S, Kerrigan D. Mantsios A, et al. Among authors: margolis d. AIDS Behav. 2020 Dec;24(12):3473-3481. doi: 10.1007/s10461-020-02918-x. AIDS Behav. 2020. PMID: 32410051 Clinical Trial.
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial.
Kerrigan D, Murray M, Sanchez Karver T, Mantsios A, Walters N, Hudson K, Kaplan-Lewis E, Pulido F, Bassa AC, Margolis D, Galai N. Kerrigan D, et al. Among authors: margolis d. AIDS Res Hum Retroviruses. 2021 Mar;37(3):207-213. doi: 10.1089/AID.2020.0208. Epub 2021 Jan 19. AIDS Res Hum Retroviruses. 2021. PMID: 33323029 Clinical Trial.
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
Kerrigan D, Mantsios A, Gorgolas M, Montes ML, Pulido F, Brinson C, deVente J, Richmond GJ, Beckham SW, Hammond P, Margolis D, Murray M. Kerrigan D, et al. Among authors: margolis d. PLoS One. 2018 Jan 5;13(1):e0190487. doi: 10.1371/journal.pone.0190487. eCollection 2018. PLoS One. 2018. PMID: 29304154 Free PMC article. Clinical Trial.
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR. Markowitz M, et al. Among authors: margolis da. Lancet HIV. 2017 Aug;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1. Epub 2017 May 22. Lancet HIV. 2017. PMID: 28546090 Clinical Trial.
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, Swindells S, Bredeek UF, Deltoro MG, García RR, Antela A, Garris C, Shaefer M, Gomis SC, Bernáldez MP, Kerrigan D. Mantsios A, et al. Among authors: margolis d. Cult Health Sex. 2021 Aug;23(8):1066-1078. doi: 10.1080/13691058.2020.1752397. Epub 2020 May 21. Cult Health Sex. 2021. PMID: 32436478
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, Lombaard J, Katner H, Walmsley S, Khuong-Josses MA, Hudson K, Dorey D, Griffith S, Spreen W, Vanveggel S, Shaefer M, Margolis D, Chounta V. Murray M, et al. Among authors: margolis d. AIDS Behav. 2020 Dec;24(12):3533-3544. doi: 10.1007/s10461-020-02929-8. AIDS Behav. 2020. PMID: 32447500 Free PMC article.
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, Liu A, Siegel M, Bertha M, Panchia R, Li S, Cottle L, Rinehart A, Margolis D, Jennings A, McCauley M, Landovitz RJ. Tolley EE, et al. Among authors: margolis d. AIDS Behav. 2020 Sep;24(9):2520-2531. doi: 10.1007/s10461-020-02808-2. AIDS Behav. 2020. PMID: 32052214 Free PMC article. Clinical Trial.
1,139 results